Back to results
US 2024/0252512 A1Published application
PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4- OXAZEPANE-2-CARBOXAMIDE
AssigneeAstraZeneca AB
InventorsHåkan WIKSTRÖM, Jufang Wu LUDVIGSSON, Thomas ANDERSSON
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof.
Claims11
A pharmaceutical composition comprising:
- (a) from about 3 wt % to about 10 wt % of (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenylethyl}-1,4-oxazepane-2-carboxamide (Compound A);
- (b) from about 55 wt % to about 70 wt % microcrystalline cellulose;
- (c) from about 18 wt % to about 22 wt % dibasic calcium phosphate dihydrate,
- (d) from about 3.5 wt % to about 4.5 wt % sodium starch glycolate;
- (e) from about 0.05 wt % to about 0.25 wt % silicon dioxide;
- and
- (f) from about 2.5 wt % to about 4.5 wt % glycerol behenate;
- and wherein the weights of components (a)-(f) add up to 100 wt %.
5 more elements
2-6. (canceled)
9-17. (canceled)
23-58. (canceled)
Dependencies are inferred from the claim text.